trending Market Intelligence /marketintelligence/en/news-insights/trending/ZIvLqv6WJQH0wMKxWLfPvQ2 content esgSubNav
In This List

Getinge to acquire Applikon Biotechnology for 840M Swedish kronor

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Getinge to acquire Applikon Biotechnology for 840M Swedish kronor

Getinge AB agreed to acquire privately held Dutch company Applikon Biotechnology BV for 840 million Swedish kronor in cash.

Under the agreement, the Swedish healthcare company will purchase all of Applikon Biotechnology's outstanding common shares. Getinge could pay up to 630 million kronor in additional earnout fees in 2021-2022 upon the achievement of certain earnings performance in 2020-2021.

Getinge said it does not expect any material impact on its 2020 earnings.

The acquisition, which will be financed through debt, is expected to close during the first quarter of 2020.

Deutsche Bank is Getinge's exclusive financial adviser and NautaDutilh the legal adviser for the deal.

As of Dec. 18, US$1 was equivalent to 9.42 Swedish kronor.